What Cencora does

Cencora (NYSE: COR), formerly AmerisourceBergen, is a US-headquartered global pharmaceutical solutions company operating one of the three large-scale wholesale drug distribution networks in the United States (alongside McKesson and Cardinal Health, collectively holding 90%+ of the US wholesale market). The company is headquartered in Conshohocken, Pennsylvania, ranks #10 on the Fortune 500, and reports annual revenue in excess of $300 billion across 50+ countries and 1,300+ operational locations, supported by a workforce of 46,000-51,000+ employees. Cencora operates 40+ distribution centers processing approximately 4,100 orders per day per facility, with 2,533 active customer accounts and 1,707 shipping points per distribution center on average.

The company's core offering is pharmaceutical distribution — wholesale and specialty — augmented by commercialization services, patient access and adherence programs, regulatory and pharmacovigilance support (notably through PharmaLex), animal health distribution (via MWI Animal Health), and increasingly, specialty physician practice management through acquired MSO platforms including OneOncology, Retina Consultants of America, and EyeSouth Partners. The underlying technology infrastructure includes controlled-substance handling and cold-chain logistics for biologics and cell therapies, chargeback and rebate processing platforms, and a newly launched next-generation inventory platform called Nucleus. Cencora also operates in advanced therapy distribution via a strategic partnership with Kite Pharma (Gilead) for CAR T-cell therapies.

Cencora's business model combines transaction-based distribution fees (per-unit margins on pharmaceutical flow-through), professional and consulting services revenue (regulatory, commercialization, pharmacovigilance), managed services contracts with manufacturers, and equity earnings from non-controlled entities (notably the retained 34.3% stake in the combined MWI/Covetrus animal-health entity). Pricing is volume-driven on the wholesale side and contract/engagement-based on services. Customer segments span global pharmaceutical manufacturers (Bristol Myers Squibb, Gilead/Kite, Kedrion among named enterprise relationships), specialty pharmacies, independent and chain retail pharmacies, hospitals and health systems, and — increasingly — owned specialty physician practices that generate downstream drug utilization. AI/ML capabilities are deployed as productivity-enhancing features across regulatory document processing, pharmacovigilance, clinical trial analytics, and supply-chain optimization rather than as a standalone product line.

Name

Cencora

Legal name

Cencora, Inc.

Website

https://cencora.com

Company type

Public

Founded year

1985

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cencora (NYSE: COR) is a US-headquartered global pharmaceutical wholesale distributor and commercialization services provider, operating one of three networks controlling 90%+ of US pharma distribution, serving manufacturers, pharmacies, health systems, and increasingly specialty physician practices across 50+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Conshohocken

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Distribution: Cencora generates the majority of its revenue through wholesale and specialty distribution of pharmaceutical products to healthcare providers, pharmacies, and health systems across its global network. The company operates over 40 distribution centers in the US and maintains presence in 50+ countries, distributing brand drugs, generic drugs, consumer products, and hospital supplies.
2. Specialty Solutions and Physician Practice Management: Following acquisitions of Retina Consultants of America and OneOncology, Cencora generates revenue from management services organizations (MSOs) providing specialty care through affiliated physician networks. This includes enhanced margins from specialty drug distribution and practice management services.
3. Commercialization Support Services: Cencora provides pharmaceutical manufacturers with market access strategy, regulatory affairs, quality management, real-world evidence, and health economics outcomes research services to support product launches and commercialization.
4. Patient Access and Adherence Support: Services to pharmaceutical companies including patient support programs, nursing and home care services, and adherence programs that help patients access and stay on prescribed therapies.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Cencora is a global pharmaceutical solutions organization that distributes brand-name, generic, and specialty pharmaceutical products, consumer health products, and hospital supplies through a network of wholesale and specialty distribution centers. The company also provides commercialization support, drug research and clinical development services, patient access and adherence programs, and physician practice management services (MSOs) for specialty practices in oncology, retina care, and other therapeutic areas.

Product overview

Cencora is a Fortune 10 pharmaceutical solutions organization offering a broad platform of integrated services spanning the pharmaceutical product lifecycle — from drug development and clinical trials through commercialization, distribution, and patient access. The platform is organized around two structural layers: (1) distribution and logistics infrastructure — including wholesale and specialty distribution networks (via AmerisourceBergen Drug Corporation, Alliance Healthcare), specialty distribution, unit-dose packaging (American Health Packaging), and the European distribution network; and (2) higher-margin specialty services — including the Retina Consultants of America MSO platform, the OneOncology community oncology MSO platform, commercialization and regulatory services (via PharmaLex), patient access and adherence programs (via Innomar Strategies, Lash Group, TheraCom), and animal health distribution (MWI Animal Health, being merged into Covetrus). The portfolio also includes proprietary technology solutions such as the Nucleus® inventory management platform and the Sure Supply drug shortage mitigation program. Cencora operates in over 50 countries with more than $300 billion in annual revenue, serving pharmaceutical manufacturers, health systems, physician practices, pharmacies, and government entities.

Differentiator

Problem solved

Functional benefit

Brands

• Alliance Healthcare: European pharmaceutical distribution brand serving hospitals, pharmacies, and providers with a broad range of products including branded and generic medicines, OTC products, health and beauty items, medical devices, and specialty products.
• AmerisourceBergen Drug Corporation (ABDC)
• ASD Healthcare
• BESSE
• American Health Packaging (AHP)
• BluePoint Laboratories
• Innomar Strategies
• PharmaLex
• World Courier
• InnomarClinics
• Alcura
• Alphega Pharmacy

Products and services

• Wholesale Distribution Networks Cencora's wholesale distribution network supplies brand and generic drugs, consumer products, and hospital supplies across the U.S., operating over 40 strategically located distribution centers under brands including ASD Healthcare, BESSE, and AmerisourceBergen Drug Corporation.
• Specialty Distribution Networks
• Alliance Healthcare (Europe) A Cencora subsidiary serving hospitals, pharmacies, and providers across Europe with a broad product range including branded and generic medicines, OTC products, health and beauty items, medical devices, and specialty products through an extensive pharmacy network and online portal.
• AmerisourceBergen Drug Corporation (ABDC) Operating over 40 U.S. distribution centers, ABDC offers brand and specialty pharmaceutical distribution through brands including ASD Healthcare and BESSE, with robust e-commerce platforms enabling efficient ordering for medical practices and pharmacies.
• American Health Packaging (AHP) Provides serialized, barcoded unit-dose products for hospital, institutional, and long-term care facilities, ensuring Bar Code Medication Administration (BCMA)-compliant medications that scan correctly at the bedside to improve patient safety and reduce waste.
• BluePoint Laboratories A trusted U.S. generic pharmaceutical drug provider delivering high-quality generic drugs at competitive prices through a secure supply chain.
• Nucleus® Inventory Management Solution A proprietary specialty physician practice inventory management platform featuring modular cabinet design, integrated touchscreen, and unified interface for medication workflow efficiency, inventory visibility, and patient care coordination.
• Patient Access and Adherence Support A suite of services designed to address barriers to patient access and accelerate speed-to-therapy, including patient support programs, adherence programs, nursing and home care services, and hub consulting — delivered through organizations including Lash Group and TheraCom (now divested to CareMetx).
• Innomar Strategies Canada's leading patient support program service provider, operating a comprehensive national network of full-service specialty reimbursement and support programs, customizing each to ensure product success and timely patient access to therapies.
• Cencora PharmaLex Helps biopharma companies navigate global regulatory and cost challenges with expertise spanning regulatory affairs, pharmacovigilance, quality management, health economics, and market access across key regions worldwide.
• Commercialization Support Integrated services spanning market access strategy, regulatory affairs and CMC, quality management and compliance, real-world evidence, health economics outcomes research (HEOR), channel strategy, market research and insights, and pharmacovigilance — supporting product launches from pre-launch through post-launch optimization.
• Drug Research and Clinical Development Support Services that streamline the drug development process and minimize go-to-market risk, including consulting, regulatory strategy, trial support, and evidence generation.
• Pharmacy Solutions Solutions enabling pharmacies to build, scale, accelerate growth, deliver stronger clinical results, and enhance patient care through tailored and scalable support.
• Practice and Clinic Solutions Solutions for specialty physician practices, including the Retina Consultants of America MSO network and community oncology practices, elevating the patient experience and expanding care possibilities through practice solutions.
• MWI Animal Health A major global distributor of animal health products, including ultra-low temperature (-80°C) fulfillment capabilities for veterinary stem cell therapies.
• Sure Supply Program A drug shortage mitigation program that allows health systems to commit to a six-month safety net reserve of critical medications at risk of shortage, spanning a variety of disease states.
• World Courier Specialized global logistics company for temperature-sensitive pharmaceutical and biological shipments.
• Logistics and Warehousing Global network for safe, secure storage and timely delivery of pharmaceutical products worldwide, with temperature-controlled capabilities and next-day shipping from strategic distribution complexes.
• Hospital and Health System Solutions Strategic innovation partnership solutions for hospital systems solving critical problems, planning for sustainable growth, and creating better health outcomes through product access, distribution, business analytics, technology, and clinical solutions.

Quantifiable outcome

• Distributors help prevent up to $78 billion per year in increased healthcare costs if manufacturers had to ship directly to healthcare providers
• +3 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Kite (Gilead Company)coreStrategic or Co-development Partner · 4 June 2026Cencora has entered an agreement with Kite, a Gilead Company, to distribute Kite's FDA-approved CAR T-cell therapies Yescarta and Tecartus across authorized treatment centers in the United States. The partnership leverages Cencora's specialty distribution infrastructure to reduce administrative burdens and provider barriers as Kite expands its treatment center network. The collaboration is designed to improve patient access to these individualized cell therapies at health systems and community oncology practices.
• CareMetxminorOthers · 27 April 2026CareMetx acquired Cencora's U.S.-based patient services and free goods pharmacy operations, including the Lash Group hub consulting services and TheraCom free goods pharmacy operations. The transaction significantly expands CareMetx's scale as an independent patient access platform in the specialty therapy market.
• CovetruscoreStrategic or Co-development Partner · 18 February 2026Cencora agreed to merge its MWI Animal Health subsidiary with Covetrus in a $3.5 billion transaction. Under the deal terms, Cencora will receive $1.25 billion in cash proceeds, $800 million in preferred equity, and retain a non-controlling 34.3% common equity stake in the combined company. The merger combines MWI's supply chain and distribution infrastructure with Covetrus' technology-enabled veterinary solutions to create an integrated animal health platform.
• NextPharma Logistics (CapVest)coreStrategic or Co-development Partner · 17 October 2025Cencora announced its acquisition of NextPharma Logistics from CapVest. The acquisition adds to Cencora's global logistics operations, expanding its capabilities in pharmaceutical supply chain management.
• Canadian Blood ServicesminorStrategic or Co-development PartnerCencora developed a customized process to support a pilot project between Canadian Blood Services and an external provider to deliver plasma-derived blood products directly to patients in Alberta, Canada, improving patient experience and process efficiency.
• GallantminorStrategic or Co-development PartnerGallant announced a fulfillment agreement with MWI Animal Health to create the first ultra-low temperature cold chain in veterinary medicine, enabling delivery of its potential first FDA-approved off-the-shelf stem cell therapy for cats.
• Curant RareminorStrategic or Co-development PartnerCencora partnered with Curant Rare, a specialty pharmacy, to accelerate the delivery of treatments for rare diseases to patients. The collaboration combines Cencora's global logistics and market access support with Curant Rare's patient engagement tools.

Scale indicators16 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• McKesson Corporation: McKesson is the largest US pharmaceutical wholesaler and the most direct comparable to Cencora, competing head-to-head across wholesale distribution, specialty distribution, and biopharma services. Together with Cencora and Cardinal Health, McKesson controls 90%+ of US pharmaceutical wholesale distribution.
• Cardinal Health: Cardinal Health is the third member of the Big 3 US pharmaceutical wholesale oligopoly, offering comparable wholesale distribution, specialty pharmaceutical distribution, and at-home solutions. It serves the same healthcare provider, pharmacy, and manufacturer customer base as Cencora with overlapping product portfolios.
• Owens & Minor: Owens & Minor is a medical/surgical product distributor serving hospitals, healthcare providers, and home health agencies. While more focused on medical-surgical than pharmaceuticals, it competes with Cencora's American Health Packaging unit-dose business and shares healthcare distribution economics, customer overlap, and supply chain operational similarity.
• Henry Schein: Henry Schein is a distributor of healthcare products to office-based dental, medical, and animal health practitioners. Its animal health segment directly competes with Cencora's MWI Animal Health business, and its overall distribution model, customer base (physician practices), and product breadth are highly comparable.
• Covetrus: Covetrus is a global animal health distribution and technology company currently merging with Cencora's MWI Animal Health in a $3.5B transaction. The two entities combine supply chain and distribution infrastructure with technology-enabled veterinary solutions, making Covetrus the closest direct peer in animal health distribution.
• Patterson Companies: Patterson Companies distributes dental, veterinary, and rehabilitation/animal health products to North American practitioners. Its animal health segment competes with Cencora's MWI business, and the company shares comparable distribution economics, customer concentration in office-based practices, and supply chain characteristics.
• UDG Healthcare (Ashfield): Ashfield, part of UDG Healthcare (acquired by CD&R), provides pharmaceutical commercialization, patient services, medical communications, and consulting — directly competing with Cencora's PharmaLex, Innomar Strategies, and commercialization support offerings for the same biopharma clients.

Broad incumbents

• Walgreens Boots Alliance: Walgreens Boots Alliance is a global pharmacy-led health and beauty retailer whose Alliance Healthcare wholesale business Cencora acquired for $6.3B in 2021. As a former parent of a Cencora subsidiary, Walgreens shares deep familiarity with pharmaceutical distribution economics and serves as both a major customer and a vertical competitor in retail pharmacy.
• CVS Health: CVS Health operates an integrated pharmacy, PBM (Caremark), and healthcare services platform that interacts with Cencora across the pharmaceutical supply chain — both as a major distribution customer and through overlapping patient access/adherence services. The new Cencora CFO (Eva C. Boratto) comes directly from CVS Health, highlighting industry personnel interconnections.

Emerging players

• Catalent: Catalent is a global contract development and manufacturing organization (CDMO) serving biopharma. While focused on drug development/manufacturing rather than distribution, Catalent competes with Cencora's PharmaLex for biopharma services wallet and shares the same life sciences customer base for commercialization, regulatory, and patient access support.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Healthcare_ABC
• Facebookfacebook.com/Cencora
• LinkedInlinkedin.com/company/cencoraglobal
• Instagraminstagram.com/cencoraglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries10 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A27 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cencora